ExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.The PlacMalVac project started in 2013 as an international consortium project funded by several parties (see below). The aim was to develop a vaccine against placental malaria,